Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis

TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

(2018) Álvaro de Mingo Pulido et al.   CANCER CELL

Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody

(2018) Kyoko Yamaguchi et al.   CANCER SCIENCE

Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients

(2017) Yang Zhang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells

(2017) Michel Enamorado et al.   Nature Communications

Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa

(2017) Yichen Chen et al.   OncoImmunology

Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma

(2016) S. Bo hm et al.   CLINICAL CANCER RESEARCH

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer

(2016) M. Rita I. Young et al.   INTERNATIONAL JOURNAL OF CANCER

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

(2015) Shin Foong Ngiow et al.   CANCER RESEARCH

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

(2015) Anna Śledzińska et al.   Molecular Oncology

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

(2013) Justyna Kmiecik et al.   JOURNAL OF NEUROIMMUNOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck

(2011) Anna-Maria A. De Costa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE